New hope for rare disease: drug may ease skin hardening in systemic sclerosis
NCT ID NCT05300932
First seen Jan 28, 2026 · Last updated May 12, 2026 · Updated 11 times
Summary
This study tests whether baricitinib, a drug that calms the immune system, can help people with systemic sclerosis—a rare disease that causes skin to harden and can affect organs like the lungs and heart. About 60 adults with early-stage disease will receive either baricitinib or a placebo for 24 weeks. The main goal is to see if the drug reduces skin thickness, measured by a standard scoring method.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of RheumatologyTongji Hospital
Wuhan, Hubei, 430030, China
-
Tongji Hospital
Wuhan, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.